Seminars in Diagnostic Pathology
Volume 26, Issue 2 , Pages 103-115 , May 2009

Neuropathology of cerebrovascular diseases

  • Lili-Naz Hazrati, MD, PhD, FRCPC

      Affiliations

    • Corresponding Author InformationAddress reprint requests and correspondence: Lili-Naz Hazrati, MD, PhD, FRCPC, University of Toronto, Department of Laboratory Medicine and Pathobiology, University Health Network, Toronto General Hospital, 200 Elizabeth Street, E11, Toronto, ON, M5G 2C4, Canada
    • ,
  • Catherine Bergeron, MD, FRCPC
    • ,
  • Jagdish Butany, MBBS, MS, FRCPC

References 

  1. Longstreth WT, Bernick C, Fitzpatrick A, et al. Frequency and predictors of stroke death in 5888 participants in the cardiovascular health study. Neurology. 2001;56:368–375
  2. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–e151
  3. Pappachan J, Kirkham FJ. Cerebrovascular disease and stroke. Arch Dis Child. 2008;93:890–898
  4. Roach ES, Golomb MR, Adams R, et al. American Heart Association Stroke Council (Council on Cardiovascular Disease in the Young. Management of stroke in infants and children: A scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young). Stroke. 2008;39:2644–2691
  5. Flynn RW, MacWalter RS, Doney AS. The cost of cerebral ischaemia. Neuropharmacology. 2008;55:250–256
  6. Terent A. Trends in stroke morbidity. In:  Whisnant J editors. Stroke: Populations, Cohorts, and Clinical Trials. Oxford: Butterworth-Heineman; 1993;p. 37–58
  7. Terent A. Trends in stroke incidence and 10-year survival, 1975-2001. Stroke. 2003;34:1353–1358
  8. Rafii MS, Hillis AE. Compendium of cerebrovascular diseases. Int Rev Psychiatry. 2006;18:395–407
  9. Strong SH, Halperin JL. Confronting atrial fibrillation in the elderly: Stroke risk stratification and emerging antithrombotic therapies. Geriatrics. 2007;62:22–27
  10. Badimon L, Vilahur G. Platelets, arterial thrombosis and cerebral ischemia. Cerebrovasc Dis. 2007;24(suppl 1):30–39
  11. Bousser MG, Ferro JM. Cerebral venous thrombosis: An update. Lancet Neurol. 2007;6:162–170
  12. Caplan LR, Fisher M. The endothelium, platelets, and brain ischemia. Rev Neurol Dis. 2007;4:113–121
  13. Kirkham FJ. Therapy insight: Stroke risk and its management in patients with sickle cell disease. Nat Clin Practice Neurol. 2007;3:264–278
  14. Scheid R, Teich N. Neurologic manifestations of ulcerative colitis. Eur J Neurol. 2007;14:483–493
  15. Joubert J, Cumming TB, McLean AJ. Diversity of risk factors for stroke. J Neurol Sci. 2007;262:71–76
  16. Solenski NJ. Emerging risk factors for cerebrovascular disease. Curr Drug Targets. 2007;8:802–816
  17. Yang LK, Wong KC, Wu MY, et al. Correlations between folate, B12, homocysteine levels, and radiological markers of neuropathology in elderly post-stroke patients. J Am Coll Nutr. 2007;26:272–278
  18. Zalba G, Fortuno A, San Jose G, et al. Oxidative stress, endothelial dysfunction and cerebrovascular disease. Cerebrovasc Dis. 2007;24(suppl 1):24–29
  19. Siennicki-Lantz A, Reinprecht F, Wollmer P, et al. Smoking-related changes in cerebral perfusion in a population of elderly men. Neuroepidemiology. 2008;30:84–92
  20. Tyas SL, White LR, Petrovitch HW, et al. Mid-life smoking and late-life dementia: The Honolulu-Asia aging study. Neurobiol Aging. 2003;24:589–596
  21. Gil-Nunez A. The metabolic syndrome and cerebrovascular disease: Suspicion and evidence. Cerebrovasc Dis. 2007;24(suppl 1):64–75
  22. Hettema ME, Bootsma H, Kallenberg CG. Macrovascular disease and atherosclerosis in SSc. Rheumatology. 2008;47:578–583
  23. Selvarajah D, Tesfaye S. Central nervous system involvement in diabetes mellitus. Curr Diab Rep. 2006;6:431–438
  24. Betts J, Jaros E, Perry RH, et al. Molecular neuropathology of MELAS: Level of heteroplasmy in individual neurones and evidence of extensive vascular involvement. Neuropathol Appl Neurobiol. 2006;32:359–373
  25. Hegele RA, Dichgans M. Update on the genetics of stroke and cerebrovascular disease 2007. Stroke. 2008;39:252–254
  26. Natowicz M, Kelley RI. Mendelian etiologies of stroke. Ann Neurol. 1987;22:175–192
  27. Auer RN, Wieloch T, Olsson Y, Siesjø BK. The distribution of hypoglycemic damage. Acta Neuropathol (Berl). 1984;64:177–191
  28. Miyamoto O, Auer RN. Hypoxia, hyperoxia, ischemia, and brain necrosis. Neurology. 2000;54:362–371
  29. Tanne D. Impaired glucose metabolism and cerebrovascular diseases. Adv Cardiol. 2008;45:107–113
  30. Esiri MM, Wilcock GK, Morris JH. Neuropathological assessment of the lesions of significance in vascular dementia. J Neurol Neurosurg Psychiatry. 1997;63:749–753
  31. Hulette C, Nochlin D, McKeel D, et al. Clinical-neuropathologic findings in multi-infarct dementia: A report of six autopsied cases. (see comment) Neurology. 1997;48:668–672
  32. Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J Neurol Sci. 2007;257:80–87
  33. Kertesz A, Chertkow H. Diagnosis and treatment of dementia. 2. Diagn CMAJ Can Med Assoc J. 2008;178:825–836
  34. Knopman DS. Cerebrovascular disease and dementia. Br J Radiol. 2007;80:S121–S127
  35. Mills S, Cain J, Purandare N, Jackson A. Biomarkers of cerebrovascular disease in dementia. Br J Radiol. 2007;80:S128–S145
  36. Murray ME, Knopman DS, Dickson DW. Vascular dementia: Clinical, neuroradiologic and neuropathologic aspects. Panminerva Med. 2007;49:197–207
  37. Onyike CU. Cerebrovascular disease and dementia. Int Rev Psychiatry. 2006;18:423–431
  38. Qiu C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: An update. Curr Opin Psychiatry. 2007;20:380–385
  39. Bestehorn K, Wahle K, Kirch W. Stroke risk screening of adults with hypertension: Prospective cross-sectional study in primary care. Clin Drug Invest. 2008;28:281–289
  40. Grassi G, Arenare F, Trevano FQ, et al. Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials. Curr Hypertens Rep. 2007;9:299–304
  41. Kemper T, Moss MB, Hollander W, Prusty S. Microinfarction as a result of hypertension in a primate model of cerebrovascular disease. Acta Neuropathol. 1999;98:295–303
  42. Lanari A, Silvestrelli G, De Dominicis P, et al. Arterial hypertension and cognitive dysfunction in physiologic and pathologic aging of the brain. Am J Geriatr Cardiol. 2007;16:158–164
  43. Nag S, Robertson DM. Cerebral cortical changes in acute experimental hypertension: An ultrastructural study. Lab Invest. 1977;36:150–161
  44. Papadopoulos DP, Papademetriou V. Aggressive blood pressure control and stroke prevention: Role of calcium channel blockers. J Hypertens. 2008;26:844–852
  45. Pedelty L, Gorelick PB. Management of hypertension and cerebrovascular disease in the elderly. Am J Med. 2008;121(suppl):S23–S31
  46. Skinhoj E, Standgaard S. Pathogenesis of hypertensive encephalopathy. Lancet. 1973;1:461–462
  47. Chester EM, Agamanolis DP, Banker BQ, Victor M. Hypertensive encephalopathy: A clinicopathological study of 20 cases. Neurology. 1978;28:928–939
  48. Kemper TL, Blatt GJ, Killiany RJ, Moss MB. Neuropathology of progressive cognitive decline in chronically hypertensive rhesus monkeys. Acta Neuropathol. 2001;101:145–153
  49. Torvik A, Svindland A, Lindboe CF. Pathogenesis of carotid thrombosis. Stroke. 1989;20:1477–1483
  50. Morita A, Nakayama T, Soma M. Association study between C-reactive protein genes and ischemic stroke in Japanese subjects. Am J Hypertens. 2006;19:593–600
  51. Tsimikas S, Aikawa M, Miller FJ, et al. Increased plasma oxidized phospholipids: Apolipoprotein B-100 ratio wih concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: A potential biomarker of early atherosclerotis regression. Atheroscler Thromb Vasc Biol. 2006;27:175–181
  52. Baumgartner , Sidler C, Mosso M, et al. Ischemic lacunar stroke in patients with and without potential mechanism other than small-artery disease. Stroke. 2003;34:653–659
  53. Micieli G. Vascular dementia. Neurol Sci. 2006;27(suppl 1):S37–S39
  54. Lechat PH. Prevalence of patent foramen ovale in patients with stroke. N Engl J Med. 1988;18:1148–1152
  55. Erkinjuntti T. Vascular cognitive deterioration and stroke. Cerebrovasc Dis. 2007;24(suppl 1):189–194
  56. Horowitz D, Tuhrim S, Weinberger JM, Rudolph SH. Mechanisms in lacunar infarction. Stroke. 1992;23:325–327
  57. McGuinness B, Todd S, Passmore AP, Bullock R. Systematic review: Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. J Neurol Neurosurg Psychiatry. 2008;79:4–5
  58. O'Sullivan M. Leukoaraiosis. Pract Neurol. 2008;8:26–38
  59. Garcia JH. The neuropathology of stroke. Hum Pathol. 1975;6:583–598
  60. Petito CK, Pulsinelli WA. Sequential development of reversible and irreversible neuronal damage following cerebral ischemia. J Neuropathol Exp Neurol. 1984;43:141–153
  61. Petito CK. Delayed hippocampal damage in humans following cardiorespiratory arrest. Neurology. 1987;37:1281–1286
  62. Caplan LR. Stroke treatment: Promising but still struggling. J Am Med Assoc. 1998;279:1304–1306
  63. Fisher CM. Capsular infarcts: The underlying vascular lesions. Arch Neurol. 1979;36:65–73
  64. Russell RWR. Observations on intracerebral neurysms. Brain. 1963;86:425–442
  65. Challa VR, Moody DM, Bell MA. Charcot–Bouchard aneurysm controversy: Impact of a new histological technique. J Neuropathol Exp Neurol. 1992;52:264–271
  66. Brisman JL, Song JK, Newell DW. Cerebral aneurysms. N Engl J Med. 2006;355:928–939
  67. Sasaki O: Clinicopathological study of dissecting aneurysms of the intracranial vertebral artery. J Neurosurg 75:874-882
  68. McCormick WF. The pathology of vascular (arteriovenous) malformations. J Neurosurg. 1996;24:807–816
  69. Brill J. Massive aneurysms at the base of the brain. Brain. 1969;92:535–570
  70. Morley TP, Barr HWK. Giant intracranial aneurysms: Diagnosis, course, and management. Clin Neurosurg. 1969;16:73–94
  71. Østergaard JR. Risk factors in intracranial saccular aneurysms. Acta Neurol Scand. 1989;80:81–98
  72. Tekkok IH, Ventureyra EC. Spontaneous intracranial hemorrhage of structural origin during the first year of life. Childs Nerv Syst. 1997;13:154–165
  73. Brown RD, Huston J, Hornung R, et al. Screening for brain aneurysm in the familial intracranial aneurysm study: Frequency and predictors of lesion detection. J Neurosurg. 2008;108:1132–1138
  74. Liu B, Zhang JN, Pu PY. Expressions of PDGF-B and collagen type III in the remodeling of experimental saccular aneurysm in rats. Neurol Res. 2008;30:632–638
  75. Schievink WI, Torres VE, Wiebers DO, Huston J. Intracranial arterial dolichoectasia in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1997;8:1298–1303
  76. Stehbens WE. Intracranial berry aneurysms in infancy. Surg Neurol. 1982;18:58–60
  77. Østergaard JR, Voldby B. Intracranial arterial aneurysms in children and adolescents. J Neurosurg. 1983;58:832–837
  78. Heros RC, Zervas NT, Varsos V. Cerebral vasospasm after subarachnoid hemorrhage: An update. Ann Neurol. 1983;14:599–608
  79. Ondra SL. The natural history of symptomatic arteriovenous malformations of the brain: A 24-year follow-up assessment. J Neurosurg. 1990;73:387–391
  80. Wilkins RH. Natural history of arteriovenous malformations of the brain. In:  Barrow DL editors. Intracranial Vascular Malformations. Park Ridge, IL: AANS Publications Committee; 1990;
  81. Gold AP, Ransohoff J, Carter S. Vein of Gallen malformation. Acta Neurol Scand. 1964;40(suppl):1–31
  82. Golombek SG, Ally S, Woolf PK. A newborn with cardiac failure secondary to a large vein of Galen malformation. South Med J. 2004;97:516–518
  83. Foix C, Alajouanine T. La myelite necrotique subaigue. Rev Neurol. 1962;2:1–42
  84. Minami S. Spinal arteriovenous malformation: MR imaging. Radiology. 1988;169:109–115
  85. Ebara N, Asada H, Miyagawa S. A case of multiple cavernous hemangiomas with skin and central nervous system involvement. J Dermatol. 2004;31:835–838
  86. Polymeropoulos MH, Hurko O, Hsu F, et al. Linkage of the locus for cerebral cavernous hemangiomas to human chromosome 7q in four families of Mexican-American descent. Neurology. 1997;48:752–757
  87. Sarraf D, Payne AM, Kitchen ND, et al. Familial cavernous hemangioma: An expanding ocular spectrum. Arch Ophthalmol. 2000;118:969–973
  88. Joachim C, Mori H, Selkoe D. Amyloid b-protein deposition in tissues other than brain in Alzheimer's disease. Nature. 1989;341:226–230
  89. Gudmundsson G. Hereditary cerebral hemorrhage with amyloidosis. Brain. 1972;95:387–404
  90. Hamaguchi T, Yamada M. [Genetic factors for cerebral amyloid angiopathy.]. Brain Nerve. 2008;60:1275–1283
  91. Naito KS, Sekijima Y, Ikeda S. Cerebral amyloid angiopathy-related hemorrhage in a middle-aged patient with Down's syndrome. Amyloid. 2008;15:275–277
  92. Coria F, Castano E, Frangione B. Brain amyloid in normal aging and cerebral amyloid angiopathy is antigenically related to Alzheimer's disease β-protein. Am J Pathol. 1982;129:422–428
  93. Levy E, In S. Icelandic patients with hereditary amyloid angiopathy is related to a mutation in the cystatin C gene, an inhibitor of cysteine proteases. J Exp Med. 1989;169:1771–1778
  94. Maruyama K. Immunohisochemical characterization of cerebrovascular amyloid in 46 autopsied cases using antibodies to b-protein and cystatin C. Stroke. 1990;21:397–403
  95. Mandybur TI. Cerebral amyloid angiopathy: The vascular pathology and complications. J Neuropathol Exp Neurol. 1986;45:79–90
  96. Vinters HV. Cerebral amyloid angiopathy: A critical review. Stroke. 1987;18:311–319
  97. Okazaki H, Reagan TJ, Campbell RJ. Clinicopathologic study of primary cerebral amyloid angiopathy. Mayo Clin Proc. 1979;564:22–31
  98. Kibayashi K, Mastri AR, Hirsch CS. Neuropathology of human immunodeficiency virus infection at different disease stages. Hum Pathol. 1996;27:637–642
  99. Moore PM, Cupps TR. Neurological complications of vasculitis. Ann Neurol. 1983;14:55–67
  100. Andrianakos AA, Duffy J, Suzuki M, Sharp TT. Transverse myelopathy in systemic lupus erythematosus. Ann Intern Med. 1975;83:616–624
  101. Benedict RH, Shucard JL, Zivadinov R, Shucard DW. Neuropsychological impairment in systemic lupus erythematosus: A comparison with multiple sclerosis. Neuropsychol Review. 2008;18:149–166
  102. Benseler SM, Silverman ED. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus. 2007;16:564–571
  103. Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythrematus: The role of vasculitis, heart emboli and thrombotic thrombocytopenic purpura. Ann Neurol. 1988;23:380–384
  104. Levine SR, Welch KMA. Cerebrovascular ischemia associated with lupus anticoagulant. Stroke. 1987;18:257–263
  105. Paranthaman R, Baldwin RC. Treatment of psychiatric syndromes due to cerebrovascular disease. Int Rev Psychiatry. 2006;18:453–470
  106. Herath SS, Law DB, Stride PJ, et al. A case of primary cerebral vasculitis. Med J Aust. 2008;188:547–549
  107. Csepany T, Kollar J, Sikula J, et al. Primary cerebral angiitis: A case history and literature review of its diagnosis. Ideggyogy Sz. 2005;58:183–189
  108. Ishikawa E, Tsuboi K, Takano S, et al. Primary cerebral angiitis containing marked xanthoma cells with massive intraparenchymal involvement: Case report. Neurol Med Chir. 2005;45:156–160
  109. Bhat G, Mathur DS, Saxena GN, et al. Granulomatous angiitis of the central nervous system associated with herpes zoster. J Assoc Physicians India. 2002;50:977–978
  110. Rosenblum WI, Hadfield MG, Young HF. Granulomatous angiitis with preceding varicella roster. Ann Neurol. 1978;3:374–375
  111. Masson C, Henin D, Colombani JM, Dehen H. A case of cerebral giant-cell angiitis associated with cerebral amyloid angiopathy (Favorable evolution with corticosteroid therapy). Rev Neurol. 1998;154:695–698
  112. Streichenberger N, Girard-Madoux P, Verejan I, et al. Giant cell angiitis of the central nervous system with amyloid angiopathy (A case report and review of the literature). Clin Exp Pathol. 1999;47:311–317
  113. Bostwick DG. Amphetamine induced cerebral vasculitis. Hum Pathol. 1981;12:1031–1033
  114. Pozzi M, Roccatagliata D, Sterzi R. Drug abuse and intracranial hemorrhage. Neurol Sci. 2008;29(suppl 2):S269–S270
  115. Lester J, Leyva A, Hoyos L, et al. Brain vasculitis associated with drugs. Rev Neurol. 2005;40:736–738
  116. Levine SR. Cerebrovascular complications of the use of the “crack” form of Alkaloid cocaine. N Engl J Med. 1990;323:699–704
  117. Su J, Li J, Li W, et al. Cocaine induces apoptosis in cerebral vascular muscle cells: Potential roles in strokes and brain damage. Eur J Pharmacol. 2003;482:61–66
  118. Treadwell SD, Robinson TG. Cocaine use and stroke. Postgrad Med J. 2007;83:389–394
  119. Elliott D. Migraine and stroke: Current perspectives. Neurol Res. 2008;30:801–812
  120. Jouvent E, Mangin JF, Porcher R, et al. Cortical changes in cerebral small vessel diseases: A 3D MRI study of cortical morphology in CADASIL. Brain. 2008;131:2201–2208
  121. Andreadou E, Papadimas G, Sfagos C. A novel heterozygous mutation in the NOTCH3 gene causing CADASIL. Swiss Med Wkly. 2008;138:614–617
  122. Munoz DG. Small vessel disease: Neuropathology. Int Psychogeriatr. 2003;15(suppl 1):67–69
  123. Rumbaugh JA, LaDuca JR, Shan Y, Miller CA. CADASIL: The dermatologic diagnosis of a neurologic disease (Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy). J Am Acad Dermat. 2000;43:1128–1130
  124. Mrak RE. The big eye in the 21st century: The role of electron microscopy in modern diagnostic neuropathology. J Neuropathol Exp Neurol. 2002;61:1027–1039
  125. Maeda S, Nakayama H, Isaka K, et al. Familial unusual encephalopathy of Binswanger's type without hypertension. Folia Psychiatr Neurol Jpn. 1976;30:165–177

PII: S0740-2570(09)00018-5

doi: 10.1053/j.semdp.2009.08.002

Seminars in Diagnostic Pathology
Volume 26, Issue 2 , Pages 103-115 , May 2009

Article Tools

* Image Usage & Resolution